Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets Sanofi's "Most Important" Segment; Merck Looks To "Win" China: Emerging Markets Earnings Round Up (Part 1)

This article was originally published in PharmAsia News

Executive Summary

Emerging markets continue to figure prominently in Big Pharma strategies for commanding growth, with China being the top priority. For Sanofi SA, more than one-third of its global sales now hail from EMs. Merck invested more than $100 million in EMs in Q2 while it announced it will cut back on its sales force in developed markets.
Advertisement

Related Content

Merck's $800 Million Investment In Singapore Aims To Produce Returns Elsewhere
Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets
Merck And BGI Sign Global Deal Focused On Biomarkers, Genomics
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Sanofi Continues Search For Novel Compounds In Asia, Inking Deal With India's Glenmark For Phase I Biologic
Turkey Again Slashes Drug Prices; Manufacturers And Pharmacists Cry Foul
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Advertisement
UsernamePublicRestriction

Register

SC078928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel